Carbon monoxide as a biomarker and therapeutic agent
US7678390B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 15, 2002 |
| Grant date | Mar 16, 2010 |
| Priority date | — |
| Expiry date | Jan 15, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, lung, liver, spleen, brain, skin and kidney diseases and other conditions and disease states including, for example, asthma, emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, interstitial lung diseases, idiopathic pulmonary diseases, other lung diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers, including lung, larynx and throat cancer, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular disease and pulmonary vascular thrombotic diseases such as pulmonary embolism. CO may be used to provide anti-inflammatory relief in patients suffering from oxidative stress and other conditions especially including sepsis and septic shock. In addition, carbon monoxide may be used as a biomarker or therapeutic agent for reducing respiratory distress in lung transplant patients and to reduce or inhibit oxidative stress and inflammation in transplant patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.